ADR-002K vs Anhui HygeianCells EE001

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Heart Failure

Shared mechanism: Cardiac cell therapy · full Heart Failure pipeline

ADR-002K

Developed by Rohto Pharmaceutical

Phase 2 in Heart FailureCell therapy (MSC)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: September 2028 · NCT07192211 (registry estimate)

No aligned efficacy figure on record for this race.

Anhui HygeianCells EE001

Developed by Anhui HygeianCells BioMedical

Phase 1 in Heart FailureBiologic/cell agent
Weak signal

NCT06884111 · Phase 1 · completed

Only 6 people received the drug, all in a single open, unblinded group with no placebo or comparison arm, so any change seen cannot be attributed to the drug with confidence. No results have been posted yet.

No aligned efficacy figure on record for this race.

Results for Heart Failure

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointADR-002KAnhui HygeianCells EE001
CV death or HF hospitalisation—Not reported—Not reported
HF hospitalisation—Not reported—Not reported
CV death—Not reported—Not reported
KCCQ clinical summary, change—Not reported—Not reported

CV death or HF hospitalisation

ADR-002K
—Not reported
Anhui HygeianCells EE001
—Not reported

HF hospitalisation

ADR-002K
—Not reported
Anhui HygeianCells EE001
—Not reported

CV death

ADR-002K
—Not reported
Anhui HygeianCells EE001
—Not reported

KCCQ clinical summary, change

ADR-002K
—Not reported
Anhui HygeianCells EE001
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ADR-002K: no structured comparison results are available for Heart Failure.

Anhui HygeianCells EE001: no structured comparison results are available for Heart Failure.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ADR-002K's landscape · Anhui HygeianCells EE001's landscape